PDF(Sci-hub)
Abstract：
BACKGROUND: A low platelet count before mobilization has recurrently been identified as risk factor for poor mobilization.
METHODS: To determine the relevance of this finding for peripheral blood stem cell (PBSC) mobilization, including pre-emptive or rescue plerixafor in the case of poor mobilization, we retrospectively analyzed all patients undergoing PBSC collection at our institution between January 2014 and December 2015 (n = 380).
RESULTS: In total, 99% of the patients (377/380) successfully collected a minimum of 2 × 106 CD34+ cells/kg body weight sufficient for a single transplant. Rescue or pre-emptive plerixafor was administered to 11% of the patients (42/380). No correlations between the platelet count before mobilization and the number of peripheral blood CD34+ cells or the CD34+ cell collection result were detected in the entire population or the subgroups according to diagnosis (newly diagnosed multiple myeloma, relapsed multiple myeloma, lymphoma, amyloid light-chain amyloidosis, sarcoma, or germ cell tumor). However, patients requiring pre-emptive or rescue plerixafor had a significantly lower platelet count before mobilization (217/nl vs. 245/nl; p = 0.004).
CONCLUSIONS: With the current state of the art PBSC mobilization strategies, the platelet count before mobilization was not associated with the CD34+ cell collection result but was associated with the need for pre-emptive or rescue application of plerixafor.
METHODS: To determine the relevance of this finding for peripheral blood stem cell (PBSC) mobilization, including pre-emptive or rescue plerixafor in the case of poor mobilization, we retrospectively analyzed all patients undergoing PBSC collection at our institution between January 2014 and December 2015 (n = 380).
RESULTS: In total, 99% of the patients (377/380) successfully collected a minimum of 2 × 106 CD34+ cells/kg body weight sufficient for a single transplant. Rescue or pre-emptive plerixafor was administered to 11% of the patients (42/380). No correlations between the platelet count before mobilization and the number of peripheral blood CD34+ cells or the CD34+ cell collection result were detected in the entire population or the subgroups according to diagnosis (newly diagnosed multiple myeloma, relapsed multiple myeloma, lymphoma, amyloid light-chain amyloidosis, sarcoma, or germ cell tumor). However, patients requiring pre-emptive or rescue plerixafor had a significantly lower platelet count before mobilization (217/nl vs. 245/nl; p = 0.004).
CONCLUSIONS: With the current state of the art PBSC mobilization strategies, the platelet count before mobilization was not associated with the CD34+ cell collection result but was associated with the need for pre-emptive or rescue application of plerixafor.
摘要：
背景：动员前的低血小板计数反复被确定为动员不良的危险因素。
方法：为了确定这一发现与外周血干细胞（PBSC）动员的相关性，包括在动员不力的情况下先发制人或救援计划，我们回顾性分析了2014年1月至2015年12月在我们机构接受PBSC采集的所有患者(n=380).
结果：总计，99％的患者（377/380）成功收集了至少2×106CD34细胞/kg体重，足以进行单次移植。对11%的患者(42/380)进行了抢救或抢先治疗。根据诊断（新诊断的多发性骨髓瘤，复发性多发性骨髓瘤，淋巴瘤淀粉样蛋白轻链淀粉样变性，肉瘤,或生殖细胞肿瘤）。然而,需要抢先或抢救的患者在动员前的血小板计数显着降低（217/nlvs.245/nl；p=0.004）。
结论：根据目前最先进的PBSC动员策略，动员前的血小板计数与CD34+细胞收集结果无关,但与需要先发制人或抢救应用plerixafor相关.
方法：为了确定这一发现与外周血干细胞（PBSC）动员的相关性，包括在动员不力的情况下先发制人或救援计划，我们回顾性分析了2014年1月至2015年12月在我们机构接受PBSC采集的所有患者(n=380).
结果：总计，99％的患者（377/380）成功收集了至少2×106CD34细胞/kg体重，足以进行单次移植。对11%的患者(42/380)进行了抢救或抢先治疗。根据诊断（新诊断的多发性骨髓瘤，复发性多发性骨髓瘤，淋巴瘤淀粉样蛋白轻链淀粉样变性，肉瘤,或生殖细胞肿瘤）。然而,需要抢先或抢救的患者在动员前的血小板计数显着降低（217/nlvs.245/nl；p=0.004）。
结论：根据目前最先进的PBSC动员策略，动员前的血小板计数与CD34+细胞收集结果无关,但与需要先发制人或抢救应用plerixafor相关.
